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ABSTRACT: Over the past decade, bioprinting has emerged
as a promising patterning strategy to organize cells and
extracellular components both in two and three dimensions
(2D and 3D) to engineer functional tissue mimicking
constructs. So far, tissue printing has neither been used for
3D patterning of mesenchymal stem cells (MSCs) in
multiphase growth factor embedded 3D hydrogels nor been
investigated phenotypically in terms of simultaneous diﬀer-
entiation into diﬀerent cell types within the same micro-
patterned 3D tissue constructs. Accordingly, we demonstrated a biochemical gradient by bioprinting nanoliter droplets
encapsulating human MSCs, bone morphogenetic protein 2 (BMP-2), and transforming growth factor β1 (TGF- β1),
engineering an anisotropic biomimetic ﬁbrocartilage microenvironment. Assessment of the model tissue construct displayed
multiphasic anisotropy of the incorporated biochemical factors after patterning. Quantitative real time polymerase chain reaction
(qRT-PCR) results suggested genomic expression patterns leading to simultaneous diﬀerentiation of MSC populations into
osteogenic and chondrogenic phenotype within the multiphasic construct, evidenced by upregulation of osteogenesis and
condrogenesis related genes during in vitro culture. Comprehensive phenotypic network and pathway analysis results, which were
based on genomic expression data, indicated activation of diﬀerentiation related mechanisms, via signaling pathways, including
TGF, BMP, and vascular endothelial growth factor.
KEYWORDS: 3D bioprinting, micropatterning, biomimetic tissue platforms, functional tissue models, tissue interfaces,
genomic expression analysis
■ INTRODUCTION
Recent advances in tissue engineering have enabled engineered
3D tissue structures for various applications, including
regenerative medicine and in vitro biomimetic functional tissue
platforms.1−16 Engineered 3D tissue models that mimic native
tissues have emerged and started playing an important role in
drug discovery and development.17−19 The need for complex
microengineered 3Dmethods for tissue engineering applications
is well accepted due to the limitations of 2D systems in eﬀectively
representing the complex tissue environment.20−22 Current 3D
tissue scaﬀolding methods present shortcomings due to lack of
control over spatial and temporal control over cell seeding and
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extracellular matrix (ECM) composition.4,13,22−24 To engineer
3D biomimetic multiphase complex tissue structures such as
tissue interfaces, it is critical to have control over the
microenvironment components, including cellular, extracellular,
and biological factor gradients in microscale. As a result of recent
advances in stem cell biology, it is possible to create
microenvironments which can direct controlled diﬀerentiation
of cells and, hence, facilitate reorganization of the bioengineered
structures toward a speciﬁc tissue phenotype.25
Designs involving single-phasic,26,27 dual-phasic,28 and con-
tinuous-gradation29 scaﬀolds have been developed. However, the
small scale of the tissue interfaces (Figure 1A,B), which range
from 50 μm to 2 mm in length (depending on tissue, species and
age),30,31 presents signiﬁcant challenges in engineering the
microscale anisotropy observed in extracellular, biochemical, and
cellular composition.32 Therefore, in the case of interface tissue
engineering, there is an unmet need for advanced biomanufactur-
ing methods to mimic the intricate microscale 3D anisotropic
environment with precision. Bioprinting can overcome the
limitations of existing tissue scaﬀolding methods in interface
tissue engineering by providing control over encapsulation and
patterning of the cells and the accompanying ECM components
in microscale.23,33
Bioprinting involves the use of computer-aided transfer
processes for patterning and assembling living and nonliving
materials with a prescribed 2D or 3D organization to produce
bioengineered structures serving in regenerative medicine, drug
discovery, and basic cell biology studies.34 Bioprinting,
biomanufacturing, and multilayer fabrication methods have
been used to control cell patterning and seeding.4,1133,35−44 In
this study, we expand the use of microscale bioprinting to
facilitate engineering of the complex anisotropic ﬁbrocartilage
tissue phase via nanoliter encapsulation and printing of MSCs
along with biochemical factors and ECM components (Figure
1C,D). MSCs were used in this study as they are the common
progenitors of musculoskeletal tissues, including bone and
cartilage.45,46
Phenotypic characterization of cells within in vitro culture
models by genomic expression analysis provides essential generic
indicators and high-content biomarkers for drug testing and for
studying the impact of uncharacterized perturbations on
cells.17,47,48 In this work, we investigated the state of the
patterned cells within the 3D multiphasic tissue constructs in
terms of a comprehensive genomic expression analysis, which is
directly relevant to development of new in vitro functional
models and their use in drug discovery. Through genomic
expression analysis, we demonstrate the potential of bioprinting
in engineering functional biomimetic multiphase 3D tissue
models, such as the ﬁbrocartilage phase at the soft and hard tissue
interface.
■ EXPERIMENTAL SECTION
Micropatterning and in Vitro Culture of Fibrocartilage
Phase. A computer-aided design of the bioprinting pathway was
ﬁrst generated (Figure 2A) for each experimental group.
Microdroplets of Bioinks were generated in a sterile laminar
ﬂow hood under controlled humidity by cell-encapsulating
droplet generation system developed in our laboratory.9,33,50,51
Using the valve-based droplet ejector setup, the Bioink droplets
composed of cell encapsulating hydrogel were printed on gel-
coated substrates (Transwell permeable culture inserts, Corning
Inc., Figure 2B). The nominal droplet size was around 300 μm in
diameter following deposition on the substrate (Figure 2C,D).
The interdroplet distance was determined by the size of the
droplets residing on the substrate, which was around 700 μm
measured from center to center (Figure 2D). Multiple layers of
these droplets were printed and photo-cross-linked layer-by-
layer using ultraviolet light (UV) at a power setting of 6.9 mW/
cm2 for 30 s based on earlier work.4 Bioprinted and photo-cross-
linked multiple layers were merged forming a seamless and
continuous 3D tissue structure (Figure 2D). Methacrylated
gelatin precursor solution (5%) with photoinitiator for photo-
cross-linking (0.5%, Irgacure 2959) was used as the major
constituent of the Bioink, as we described previously.4 Diﬀusion
and integration of the phases were assessed using the ﬂuorescent
Rhodamine B (red; 0.04 mM; 479 Da) and Dextran-Alexa Fluor
488 (green; 0.01 mM; 10 kDa). To bioprint the ﬁbrocartilage
phase, hydrogel solution was supplemented with human MSCs
(hMSCs, Lonza) at a concentration of 106 cells per milliliter of
hydrogel and growth factors (BMP-2 at 20 ng per mL of
hydrogel; TGF-β1 at 10 ng per mL of hydrogel; human
recombinant growth factors from R&D Systems). To maintain
cellular viability during bioprinting, Bioink was supplemented
Figure 1. Complex anisotropic organization of the ﬁbrocartilage phase
at the bone−tendon interface. (A) Both tendon and bone tissues are rich
in collagen type I with signiﬁcant diﬀerence in cellular composition.
Tendon (soft tissue) attaches to bone (hard tissue) through an
anisotropic insertion site: the ﬁbrocartilage phase. Scale bars in the
ﬁgures represent 50 μm, 1 mm, and 50 μm, respectively. (B)
Fibrocartilage phase presents an intricate gradation in terms of structure,
ECM components, cells, and biological factors in a diminutive space
(∼1−2 mm in length). (C) Fibrocartilage phase is composed of four
continuous and intertwined phases: (i) tendon (proper), (ii)
ﬁbrocartilage, (iii) mineralized ﬁbrocartilage, and (iv) bone. (D) We
mimicked the native ﬁbrocartilage phase via 3D micropatterning
nanoliter gel encapsulated hMSCs, ECM components, and composi-
tions of biochemical factors, BMP-2 and TGF-β1 in a multiphase
pattern. Tendon and bone junction photograph was adapted from
Wopenka et al.,49 copyright 2008, and reproduced with permission of
Society for Applied Spectroscopy.
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with 10% culture medium and the pH was neutralized to 7.0
using 0.1 M sodium hydroxide solution. hMSCs were mixed into
the Bioink and patterned in microdroplets with BMP-2 and
TGF- β1 growth factors in single phase or multiphase pattern
representing the ﬁbrocartilage phase. We evaluated four diﬀerent
Bioink compositions to investigate the eﬀect of bioprinting based
patterning on engineered ﬁbrocartilage phase: (1) multiphase
TGF-β1 and BMP-2 patterning with hMSCs, (2) single phase
TGF-β1 patterning with hMSCs, (3) single phase BMP-2
patterning with hMSCs, and (4) control (no growth factors,
hMSCs only). The culture medium was composed of α-MEM
(Sigma), 10% MSC-qualiﬁed-FBS (Invitrogen), 60 U/mL Pen-
Strep (Invitrogen), and 2.5 μg/mL Fungizone (Sigma), based on
our earlier work.6,13,14,16 The culture medium was changed every
two days, and all samples were maintained at 37 °C, 5% CO2,
95−99% relative humidity (to prevent dehydration) throughout
the experiment (up to 36 days). To evaluate cell viability in the
bioprinted constructs, cells were stained with ﬂuorescent dyes of
calcein-AM and propidium iodide (Live-Dead assay, Invitrogen)
after bioprinting was completed.
Quantitative RT-PCR Analysis. Extraction and isolation of
mRNA was performed separately and individually for (i) control,
(ii) single phase BMP-2, (iii) single phase TGF-β, and (iv)
multiphase BMP-2 and TGF-β groups using the TRIzol reagent
and following the manufacturer’s RNA isolation protocol
(Invitrogen). qRT-PCR array analysis was used to assess the
Figure 2.Micropatterning and bioprinting the anisotropic 3D ﬁbrocartilage phase. (A) A computer-aided drawing and a path map of the bioprinter was
developed. Experimental groups and corresponding Bioink compositions were determined. (B) Nanoliter droplets encapsulating hMSCs, ECM
components, and growth factors were deposited on a cell culture insert covered with a thin layer of hydrogel. The lower part of the insert was ﬁlled with
DPBS to keep the deposited nanoliter droplets hydrated. Each layer was photo-cross-linked using UV light to stabilize the structure. (C) The patterned
nanoliter droplets initially form a single layer structure on the insert. (D) Single layer design and layer-by-layer deposition can be repeated to achieve a
multilayered 3D tissue construct in a single phase or multiphase format. When multiple layers of these droplets are printed and cross-linked, they merge
forming a seamless and continuous 3D tissue structure.
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diﬀerentiation of hMSCs to bone, cartilage, tendon, adipose, and
muscle phenotypes after 14, 21, and 36 days of culture. Genomic
expression analysis was performed using the Human Mesen-
chymal Stem Cell RT2 Proﬁler PCR Array (PAHS-082Z,
SABiosciences, Qiagen, Valencia, CA) for the expression of 84
key genes according to manufacturer’s instructions utilizing
Roche LightCycler 480 instrument. The data generated were
analyzed using the SABioscience software. Normalization was
performed using arithmetic mean utilizing housekeeping genes
(ACTB, B2M, GAPDH, HPRT1, RPLP0). The genes were
initially categorized in terms of stemness markers, MSC-speciﬁc
markers, and other genes associated with MSCs. Stemness
markers were grouped as FGF2, INS, LIF, POU5F1, SOX2,
TERT, WNT3A, ZFP42. MSC-speciﬁc markers were catego-
rized as ALCAM, ANPEP, BMP2, CASP3, CD44, ENG, ERBB2,
FUT4, FZD9, ITGA6, ITGAV, KDR, MCAM, NGFR, NT5E,
PDGFRB, PROM1, THY1, VCAM1. Other genes associated
with MSCs were ANXA5, BDNF, BGLAP, BMP7, COL1A1,
CSF2, CSF3, CTNNB1, EGF, FUT1, GTF3A, HGF, ICAM1,
IFNG, IGF1, IL10, IL1B, IL6, ITGB1, KITLG, MITF, MMP2,
NES, NUDT6, PIGS, PTPRC, SLC17A5, TGFB3, TNF,
VEGFA, VIM, VWF. MSC diﬀerentiation markers were
categorized in four main groups: (i) genes involved in
osteogenesis and chondrogenesis, namely, BMP2, BMP4,
BMP6, COL1A1, ERBB2, FGF10, GDF6, HDF, IGF1, IL10,
IL6, KDR, LIF, RUNX2, SOX9, TBX5, TGFB1, TGFB3,
VEGFA, WNT3A; (ii) genes involved in adipogenesis, namely,
PPARG, RHOA, RUNX2; (iii) genes involved in myogenesis,
namely, JAG1, NOTCH1; and (iv) genes involved in teno-
genesis, namely, BMP2, GDF15, SMAD4, TGFB1.
Pathway and Network Analysis. Comprehensive network
and pathway analyses were performed using the qRT-PCR data
and GeneGo Metacore Software and Database. For GeneGo
Metacore pathway and network analysis, fold regulation data
obtained from qRT-PCR results were used. To eliminate the
noise level data points, intensity levels and fold change data were
compared for each sample at each time point. Fold change values
were determined relative to control group, which included only
hMSCs and did not include any growth factors. According to this
comparison, the genes were categorized in the following groups:
(i) single phase BMP-2, (ii) single phase TGF-β, and (iii)
multiphase BMP-2 and TGF-β. Before analysis, the general
threshold value was set as 1.3 and the p-value was set as 0.01 for
all time points and samples. Next, GO processes were
determined for day 14 (Table S1 in the Supporting Information),
day 21 (Table S2 in the Supporting Information), and day 36
(Table S3 in the Supporting Information) for all three categories.
Similarly, pathway maps were determined for day 14 (Figure S1
and Table S4 in the Supporting Information), day 21 (Figure S2
and Table S5 in the Supporting Information), and day 36 (Figure
S3 and Table S6 in the Supporting Information). Process
networks were obtained for day 14 (Table S7 in the Supporting
Information), day 21 (Table S8 in the Supporting Information),
and day 36 (Table S9 in the Supporting Information). Finally,
map folders (Figure S4 in the Supporting Information) were
determined for all time points using GeneGo software.
■ RESULTS AND DISCUSSION
Anisotropy and Multiphase Patterning of Engineered
3D Fibrocartilage Tissue Model.We studied the distinctness
and integration of the bioprinted phases by using large molecular
weight ﬂuorescent dyes, Rhodamine B (red) and Dextran-Alexa
Fluor 488 (green), where red color represents the TGF-β1 phase
and the green color represents the BMP-2 phase (Figure 2A−C).
The printed multiphase hydrogel structure representing an
anisotropic tissue unit displayed boundaries between the
individual droplets immediately after printing (Figure 2D).
The dyes were considered to mimic the embedded growth
factors in diﬀerent phases in constructs, and they were employed
to visualize the anisotropy after patterning (Figure 3A). Release
and delivery of growth factors from hydrogel carriers have been
extensively studied for applications in tissue engineering and
regenerative medicine.58−60 In this study, our aim was to retain
the growth factors in the patterned hydrogel constructs together
with the cells, which would assist in diﬀerentiation of embedded
stem cells toward osteogenic and chondrogenic phenotypes in
the patterned structures. Imaging after patterning indicated a
limited integration and a gradient between the two adjacent
phases, and a distinction was still present between the bulk of two
phases (Figure 3A). In a smaller scale, the boundaries were
observed to fade and smooth transitions emerged between the
two phases after the multilayer printing process was completed
Figure 3. Micropatterned anisotropic ﬁbrocartilage phase. (A) The predesigned architecture was realized via depositing and patterning nanoliter
droplets encapsulating hMSCs and compositions of TGF-β1 and BMP-2. Red color zone represents the TGF-β1 patterned section, and green color
represents the BMP-2 patterned section. Red to green color transition region in the engineered construct (indicated by dashed line) was observed to be
around ∼1−2 mm in length, which mimics the native ﬁbrocartilage interface region. Scale bar represents 500 μm of length. (B) Viability of hMSCs was
assessed via a live/dead assay one day after deposition and micropatterning of nanoliter droplets at various magniﬁcations using phase contrast and
ﬂuorescent microscopy. Cell viability was greater than 90%, indicated by green colored cells. Cells displayed typical healthy morphology in the
bioprinted constructs. Scale bars represent 500 μm of length for the upper images, and 100 μm of length for the lower images.
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(Figure 3A inset). The transition region in the tissue construct
(indicated by the dashed line in the Figure 3A inset) was
observed to be around ∼1−2 mm in length, which mimics the
native ﬁbrocartilage interface region. A similar integration
pattern between the phases was considered to be present in
the case of growth factor and cell patterning.
Most biomaterials and scaﬀolding approaches result in
mismatch of compositional properties at the tissue interface
due to the lack of the physiological anisotropy.52,53 Soft−hard
tissue interfaces between tendon, ligament, cartilage, and bone
are complex, and they are composed of four main zones: (i) soft
tissue proper, (ii) ﬁbrocartilage, (iii) mineralized ﬁbrocartilage,
and (iv) bone, in a microscale intricate organization.49
Mimicking the functional integration site of soft tendon tissue
to rigid bone tissue can be attained by regenerating the
ﬁbrocartilage phase, which requires population by multiple cell
types and associated ECMheterogeneity similar to a native tissue
interface.2 An anisotropic and stratiﬁed structure is essential to
mimic the mechanical, compositional and cellular features of the
tissue interface. The transition occurs in a microscopic space (50
μm to ∼1−2 mm, depending on species and age)30,31 with
dramatic change in cellular, ECM, and biological factor
composition (Figure 1), which could be mimicked using
bioprinting method.
Morphological Organization and Characterization of
Embedded Cells in Multiphase Patterned Tissue Struc-
ture. In an earlier study, we presented an extensive genomic
analysis of stem cell markers in bioprinted stem cells, which infer
the proliferation potential of the printed cells.50 In this study, to
test the viability of the cells after patterning, we performed
calcein-AM and propidium iodide based viability assay on the
cells. Cell viability was observed to be greater than 90% after
micropatterning (Figure 3B) in the engineered ﬁbrocartilage
phase. This result indicated that bioprinting did not signiﬁcantly
aﬀect cell survival, which is consistent with our earlier
studies.9,33,50,51 Cells displayed typical healthy morphology
generally observed in hydrogels (Figure 3B).
Genomic Expression Analysis on Single Phase and
Multiphase Patterned TissueModels.Quantitative RT-PCR
genomic expression analysis results demonstrated that most of
the osteogenesis and chondrogenesis related genes analyzed
were simultaneously upregulated in multiphase BMP-2 and
TGF-β1 patterned constructs, especially after long-term culture
(Figure 4A). Fold change values were observed to be higher for
most osteogenesis and chondrogenesis related genes in the
multiphase BMP-2 and TGF-β construct compared to single
phase constructs after 36 days in culture (Figure 4B). A number
of tendon, muscle, and adipose tissue related genes were also
expressed at lower upregulation values (Figure 5).
Various growth factors, including BMP-2 and TGF-β
superfamily factors, have previously been immobilized in
combination with ECM components by utilizing the inherent
Figure 4. Osteogenesis and chondrogenesis related genes in single phase and multiphase samples for days 14, 21, and 36. (A) Red color intensity in
osteogenesis and chondrogenesis related genes in BMP-2 and TGF-β1 patterned groups, especially after 36 days of culture, suggests simultaneous
expression of these two phenotypes in the engineered tissue constructs. (B) Fold changes were higher for most osteogenesis and chondrogenesis related
genes in the multiphase BMP-2 and TGF-β tissue construct compared to single phase constructs after 36 days in culture.
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binding ability of these cytokines and ECM components.54,55
These factors were used in combination with bioprinting to form
2D structures to study the response and diﬀerentiation of cells,
which were seeded postprinting.56,57 In this study we
incorporated BMP-2 and TGF-β1 in photo-cross-linkable gelatin
based hydrogel matrix in combination with hMSCs as a Bioink to
Figure 5. Genomic expression analysis results presented as a clustergram after three diﬀerent culture durations (days 14, 21, and 36) for both single
phase and multiphase patterning.
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form multiphase 3D tissue models. With this 3D tissue structure,
we studied phenotypic diﬀerentiation and genomic expression of
embedded hMSCs toward bone and cartilage, mimicking the
ﬁbrocartilage phase in skeletal system.
Phenotypic Pathway and Network Analysis Based on
Genomic Expression Data. General pathway analysis was
performed on genomic expression data to obtain a compre-
hensive list of all the diﬀerentiation related pathways involved in
the engineered tissue model, which is an approach directly
related to drug discovery and development. Activation of
diﬀerentiation related mechanisms, via signaling pathways,
including TGF, Wnt, BMP, and vascular endothelial growth
factor (VEGF), were analyzed and presented for qRT-PCR
results obtained at day 14 (Figure S1 in the Supporting
Information), day 21 (Figure S2 in the Supporting Information),
and day 36 (Figure S3 in the Supporting Information), with
references to the relevant literature. The speciﬁc genes identiﬁed
in each analysis and the statistical p-values calculated by the
GeneGo software are presented in Tables S1−S9 in the
Supporting Information. These results demonstrated that, at all
the time points, diﬀerentiation related pathways were activated in
the engineered ﬁbrocartilage tissues via bone and cartilage related
signaling pathways, including TGF, Wnt, BMP, and VEGF
(Figures S1−S4 in the Supporting Information). In the light of
the various pathways observed in this study, future studies are
needed that focus on speciﬁc relevant pathways involved in
diﬀerentiation of hMSCs in engineered interface tissues. The
approach and the results presented in this work are directly
relevant to development of new in vitro functional models based
on stem cells and their use in drug discovery.
■ SUMMARY AND CONCLUSIONS
We present the application of emerging bioprinting technology
in engineering anisotropic multiphase 3D tissue models with
potential impact in in vitro drug testing, discovery, and
development. We designed a biochemical gradient with
microscale gels encapsulating hMSCs and growth factors in an
organization that aims to mimic the native ﬁbrocartilage phase.
Quantitative RT-PCR analysis showed that the hMSCs displayed
an upregulation of osteogenesis and chondrogenesis related
genes simultaneously in the 3D ﬁbrocartilage model. Phenotypic
pathway and network analysis results were presented based on
the genomic expression data obtained from the model.
Bioprinted microscale anisotropic tissue structures can poten-
tially be utilized as functional in vitro 3D tissue models and
platforms for high-throughput pharmaceutical testing and
validation studies. Functional tissue models coupled with
comprehensive genomic expression analysis on high-content
biomarkers via bioinformatics data mining tools open new
venues in drug testing and discovery. These methods and
platforms would ultimately allow the use of a patient’s own cells
for generating personalized in vitro functional tissue models as
testbeds for assessing drug candidates and therapeutics.
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